Alpha 2.0
Login Register
» Authors » C Schem

C Schem

Explore the profile of C Schem including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 21
Citations 634
Followers 0
Related Specialties
Oncology
Gynecology & Obstetrics
General Medicine
Top 10 Co-Authors
S Loibl
C Denkert
G von Minckwitz
M Untch
P A Fasching
V Nekljudova
V Muller
T Karn
F Marme
J Huober
Published In
Ann Oncol
Breast Cancer Res Treat
Geburtshilfe Frauenheilkd
Hum Reprod
Anticancer Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial
Llop-Guevara A, Loibl S, Villacampa G, Vladimirova V, Schneeweiss A, Karn T, et al.
Ann Oncol . 2021 Sep; 32(12):1590-1596. PMID: 34520831
Background: Current genetic and genomic tests measuring homologous recombination deficiency (HRD) show limited predictive value. This study compares the performance of an immunohistology-based RAD51 test with genetic/genomic tests to identify...
2.
Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy
Denkert C, Untch M, Benz S, Schneeweiss A, Weber K, Schmatloch S, et al.
Ann Oncol . 2021 Jan; 32(4):500-511. PMID: 33418062
Background: Different endogenous and exogenous mutational processes act over the evolutionary history of a malignant tumor, driven by abnormal DNA editing, mutagens or age-related DNA alterations, among others, to generate...
3.
Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo
Karn T, Denkert C, Weber K, Holtrich U, Hanusch C, Sinn B, et al.
Ann Oncol . 2020 May; 31(9):1216-1222. PMID: 32461104
Background: The predictive value of tumor mutational burden (TMB), alone or in combination with an immune gene expression profile (GEP), for response to neoadjuvant therapy in early triple negative breast...
4.
Strong impact of MammaPrint and BluePrint on treatment decisions in luminal early breast cancer: results of the WSG-PRIMe study
Wuerstlein R, Kates R, Gluz O, Grischke E, Schem C, Thill M, et al.
Breast Cancer Res Treat . 2019 Feb; 175(2):389-399. PMID: 30796651
Purpose: The WSG-PRIMe Study prospectively evaluated the impact of the 70-gene signature MammaPrint® (MP) and the 80-gene molecular subtyping assay BluePrint® on clinical therapy decisions in luminal early breast cancer....
5.
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, et al.
Ann Oncol . 2019 Jan; 30(7):1180. PMID: 30624609
No abstract available.
6.
Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours-the MACBETH project
Cazzaniga M, Ciruelos E, Fabi A, Garcia-Saenz J, Lindman H, Mavroudis D, et al.
Cancer Chemother Pharmacol . 2018 Nov; 83(2):301-318. PMID: 30460489
Introduction: Despite the large use of nab-paclitaxel as a treatment option in metastatic breast cancer (MBC) across different countries, no definitive data are available in particular clinical situations. Areas Covered:...
7.
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto
Loibl S, Weber K, Timms K, Elkin E, Hahnen E, Fasching P, et al.
Ann Oncol . 2018 Oct; 29(12):2341-2347. PMID: 30335131
Background: In the neoadjuvant GeparSixto study, adding carboplatin to taxane- and anthracycline-based chemotherapy improved pathological complete response (pCR) rates in patients with triple-negative breast cancer (TNBC). Here, we present survival...
8.
Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry
Witzel I, Laakmann E, Weide R, Neunhoffer T, Park-Simon T, Schmidt M, et al.
Eur J Cancer . 2018 Aug; 102:1-9. PMID: 30099223
Background: Brain metastases (BMs) have a major impact on life expectancy and quality of life for many breast cancer patients. Knowledge about treatment patterns and outcomes is limited. Methods: We...
9.
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, et al.
Ann Oncol . 2018 Apr; 29(10):2151. PMID: 29701763
No abstract available.
10.
Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer
Villegas S, Darb-Esfahani S, von Minckwitz G, Huober J, Weber K, Marme F, et al.
Breast Cancer Res Treat . 2017 Nov; 168(1):179-187. PMID: 29177689
Purpose: Hormone receptor (HR)-positive breast cancer (BC) shows a poor response to neoadjuvant chemotherapy (NACT). New treatment targets like the Cyclin D1-CDK4/CDK6 complex are promising adjuvant/post-neoadjuvant therapeutic strategies. Evaluating Cyclin...